150 related articles for article (PubMed ID: 35885858)
1. Incidence and Risk of Anti-Resorptive Agent-Related Osteonecrosis of the Jaw after Tooth Extraction: A Retrospective Study.
Shimizu R; Sukegawa S; Sukegawa Y; Hasegawa K; Ono S; Nakamura T; Fujimura A; Fujisawa A; Nakano K; Takabatake K; Kawai H; Nagatsuka H; Furuki Y
Healthcare (Basel); 2022 Jul; 10(7):. PubMed ID: 35885858
[TBL] [Abstract][Full Text] [Related]
2. Antiresorptive agent-related osteonecrosis of the jaw risk in cancer patients before bone-modifying agent therapy: A retrospective study of 511 patients.
Kanno C; Kojima M; Tezuka Y; Yaginuma S; Kanaya Y; Kaneko T
Bone; 2023 Dec; 177():116892. PubMed ID: 37689127
[TBL] [Abstract][Full Text] [Related]
3. Antiresorptive agent-related osteonecrosis of the jaw (ARONJ) in urological malignancies: a multi-center retrospective study.
Sakai Y; Shindo T; Sato S; Takahashi A; Kunishima Y; Kato R; Itoh N; Okada M; Tachiki H; Taguchi K; Takayanagi A; Hotta H; Horita H; Matsukawa M; Matsuki M; Nishiyama K; Miyazaki A; Hashimoto K; Tanaka T; Masumori N
J Bone Miner Metab; 2021 Jul; 39(4):661-667. PubMed ID: 33704573
[TBL] [Abstract][Full Text] [Related]
4. Associations between Systemic Markers of Bone Turnover or Bone Mineral Density and Anti-Resorptive Agent-Related Osteonecrosis of the Jaw in Patients Treated with Anti-Resorptive Agents.
Tohashi K; Nakabayashi M; Kodani I; Kidani K; Ryoke K
Yonago Acta Med; 2016 Mar; 59(1):45-53. PubMed ID: 27046950
[TBL] [Abstract][Full Text] [Related]
5. Incidence and risk of antiresorptive agent-related osteonecrosis of the jaw (ARONJ) after tooth extraction in patients with autoimmune disease.
Fujieda Y; Doi M; Asaka T; Ota M; Hisada R; Ohnishi N; Kono M; Kameda H; Nakazawa D; Kato M; Amengual O; Takahata M; Yasuda S; Kitagawa Y; Atsumi T
J Bone Miner Metab; 2020 Jul; 38(4):581-588. PubMed ID: 32076874
[TBL] [Abstract][Full Text] [Related]
6. Antiresorptive agent-related osteonecrosis of the jaw in prostate cancer patients with bone metastasis treated with bone-modifying agents.
Nakai Y; Kanaki T; Yamamoto A; Tanaka R; Yamamoto Y; Nagahara A; Nakayama M; Kakimoto KI; Ishibashi M; Nishimura K
J Bone Miner Metab; 2021 Mar; 39(2):295-301. PubMed ID: 32886176
[TBL] [Abstract][Full Text] [Related]
7. Osteonecrosis of the jaw in patients transitioning from bisphosphonates to denosumab treatment for osteoporosis.
Voss PJ; Steybe D; Poxleitner P; Schmelzeisen R; Munzenmayer C; Fuellgraf H; Stricker A; Semper-Hogg W
Odontology; 2018 Oct; 106(4):469-480. PubMed ID: 29713913
[TBL] [Abstract][Full Text] [Related]
8. Antiresorptive Agent-Related Osteonecrosis of the Jaw (ARONJ): A Twist of Fate in the Bone.
Shibahara T
Tohoku J Exp Med; 2019 Feb; 247(2):75-86. PubMed ID: 30713280
[TBL] [Abstract][Full Text] [Related]
9. Evaluation of Preventive Treatment Protocols for Patients under Antiresorptive Therapy Undergoing Tooth Extraction at a Swiss University Clinic.
Pick E; Leuenberger N; Kuster I; Stutzmann NS; Stadlinger B; Valdec S
Int J Environ Res Public Health; 2021 Sep; 18(18):. PubMed ID: 34574862
[TBL] [Abstract][Full Text] [Related]
10. Bone scan index of the jaw: a new approach for evaluating early-stage anti-resorptive agents-related osteonecrosis.
Watanabe S; Nakajima K; Mizokami A; Yaegashi H; Noguchi N; Kawashiri S; Inokuchi M; Kinuya S
Ann Nucl Med; 2017 Apr; 31(3):201-210. PubMed ID: 27995542
[TBL] [Abstract][Full Text] [Related]
11. Single-center analysis of antiresorptive agent-related osteonecrosis of the jaw in lung cancer patients.
Okamura M; Fujita K; Yamamoto Y; Kanai O; Nakatani K; Horimoto K; Hashimoto M; Sawai S; Shimosato M; Yoshida K; Mio T
Asia Pac J Clin Oncol; 2020 Dec; 16(6):380-384. PubMed ID: 32893984
[TBL] [Abstract][Full Text] [Related]
12. Antiresorptive agent-related osteonecrosis of the jaw in osteoporosis patients from Asian countries.
Taguchi A; Shiraki M; Morrison A; Khan AA
Osteoporos Sarcopenia; 2017 Jun; 3(2):64-74. PubMed ID: 30775507
[TBL] [Abstract][Full Text] [Related]
13. Antiresorptive agent-related osteonecrosis of the jaw: Position Paper 2017 of the Japanese Allied Committee on Osteonecrosis of the Jaw.
; Yoneda T; Hagino H; Sugimoto T; Ohta H; Takahashi S; Soen S; Taguchi A; Nagata T; Urade M; Shibahara T; Toyosawa S
J Bone Miner Metab; 2017 Jan; 35(1):6-19. PubMed ID: 28035494
[TBL] [Abstract][Full Text] [Related]
14. CT imaging features of antiresorptive agent-related osteonecrosis of the jaw/medication-related osteonecrosis of the jaw.
Baba A; Goto TK; Ojiri H; Takagiwa M; Hiraga C; Okamura M; Hasegawa S; Okuyama Y; Ogino N; Yamauchi H; Kobashi Y; Yamazoe S; Munetomo Y; Mogami T; Nomura T
Dentomaxillofac Radiol; 2018 May; 47(4):20170323. PubMed ID: 29365278
[TBL] [Abstract][Full Text] [Related]
15. Medication-related osteonecrosis of the jaw after tooth extraction in cancer patients: a multicenter retrospective study.
Hasegawa T; Hayashida S; Kondo E; Takeda Y; Miyamoto H; Kawaoka Y; Ueda N; Iwata E; Nakahara H; Kobayashi M; Soutome S; Yamada SI; Tojyo I; Kojima Y; Umeda M; Fujita S; Kurita H; Shibuya Y; Kirita T; Komori T;
Osteoporos Int; 2019 Jan; 30(1):231-239. PubMed ID: 30406309
[TBL] [Abstract][Full Text] [Related]
16. Incidence of antiresorptive agent-related osteonecrosis of the jaw: A multicenter retrospective epidemiological study in Hyogo Prefecture, Japan.
Nashi M; Kishimoto H; Kobayashi M; Tachibana A; Suematsu M; Fujiwara S; Ota Y; Hashitani S; Shibatsuji T; Nishida T; Fujimura K; Furudoi S; Ishida Y; Ishii S; Fujita T; Iwai S; Shigeta T; Harada T; Miyai D; Takeda D; Akashi M; Noguchi K; Takenobu T
J Dent Sci; 2023 Jul; 18(3):1156-1163. PubMed ID: 37404599
[TBL] [Abstract][Full Text] [Related]
17. Major histocompatibility complex class II polymorphisms are associated with the development of anti-resorptive agent-induced osteonecrosis of the jaw.
Stockmann P; Nkenke E; Englbrecht M; Schlittenbauer T; Wehrhan F; Rauh C; Beckmann MW; Fasching PA; Kreusch T; Mackensen A; Wullich B; Schett G; Spriewald BM
J Craniomaxillofac Surg; 2013 Jan; 41(1):71-5. PubMed ID: 23218978
[TBL] [Abstract][Full Text] [Related]
18. [Incidence of Antiresorptive Agent-Related Osteonecrosis of the Jaw in Urologic Cancers].
Kawanishi H; Yokozeki H; Hoshiyama A; Watanabe H; Funahashi Y; Fujiwara M; Takashima Y; Shintani M; Yui S; Okumura K
Hinyokika Kiyo; 2022 Jan; 68(1):1-6. PubMed ID: 35114759
[TBL] [Abstract][Full Text] [Related]
19. Does inflammatory dental disease affect the development of medication-related osteonecrosis of the jaw in patients using high-dose bone-modifying agents?
Ueda N; Nakashima C; Aoki K; Shimotsuji H; Nakaue K; Yoshioka H; Kurokawa S; Imai Y; Kirita T
Clin Oral Investig; 2021 May; 25(5):3087-3093. PubMed ID: 33057886
[TBL] [Abstract][Full Text] [Related]
20. Predictive factors for refractory stage I and II anti-resorptive agent-related osteonecrosis of the jaw.
Shimizu T; Kim M; Dam TT; Kurihara J; Ogawa M; Makiguchi T; Yokoo S
Oral Radiol; 2022 Apr; 38(2):240-251. PubMed ID: 34218422
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
